MPT64 secretion as a viability-associated immunoassay readout for rapid phenotypic drug susceptibility classification of Mycobacterium tuberculosis: a proof-of-concept study.

Published 10/01/2026

Research record: MPT64 secretion as a viability-associated immunoassay readout for rapid phenotypic drug susceptibility classification of Mycobacterium tuberculosis: a proof-of-concept study.

Published in J Antimicrob Chemother; first publication date 2026-10-01. PMID 42948968.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Read the original publication on PubMed

Talk to a Specialist Browse all insights

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-10-01

Updated

2026-10-30

Disclaimer

professional use

References

MPT64 secretion as a viability-associated immunoassay readout for rapid phenotypic drug susceptibility classification of Mycobacterium tuberculosis: a proof-of-concept study.

Review and references

Explore more

Patient Experience with Phlebotomy and Laboratory Testing at a University Hospital: A Mixed-Methods Exploratory Study.

Quantification of Upadacitinib, Dasatinib, Ruxolitinib, Imatinib, and Cabozantinib in Plasma With Liquid Chromatography-Tandem Mass Spectrometry.

Diagnostic efficacy of XQ-Station POCT, real-time PCR, and Droplet Digital PCR in detecting African swine fever virus.